IRVINE, Calif., Sept. 8, 2005 (PRIMEZONE) -- "The announcement by a Harvard research team that skin cells had been converted into stem cells offers explosive possibilities," stated SmallCap Sentinel analyst D.R. Clark. "Without the need to make human eggs or create human embryos as has been part of the process in the past, many groups would likely withdraw their moral opposition to formerly controversial stem cell research."
"The technique uses laboratory-created human embryonic stem cells of the type that has already been approved by President Bush for use by federally funded researchers, to reprogram the genes in a person's skin cell, effectively modifying the skin cell into an embryonic stem cell," added Clark. "This is enormous news as it may open huge scientific doors while perhaps for the first time, uniting public opinion in support of stem cell research."
An informational report titled "Looking at the Political Impact on Stem Cell Research" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com.
New Life Scientific (OTCBB:NWLF), which endeavors to blend Eastern European research and development with Western management, Genentech, Inc. (NYSE:DNA), Sepracor Inc. (Nasdaq:SEPR), and Celgene Corporation (Nasdaq:CELG) will be discussed in the report.
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid thirty-six hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.